-2.54%
Today
Loading 1D prices…
Company profile
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Cambridge, MA, United States
Employees
81
Fiscal year end
1231
CIK
1745648
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ARDXArdelyx Inc. Common Stock | $890.7M | $407.3M | -15.22% | -$0.26 | -1.01% | Buy |
| RIGLRigel Pharmaceuticals Inc. Common Stock | $886.1M | $294.3M | +124.72% | $19.48 | +0.61% | Buy |
| TBPHTheravance Biopharma Inc. Ordinary Shares | $884.2M | $107.5M | +98.54% | $2.06 | 0.00% | Hold |
| HELPCybin Inc. Common Stock | $919.9M | $0.00 | — | -$4.25 | +0.08% | Buy |
| CYRXCryoPort Inc. Common Stock | $881.3M | $176.2M | +44.44% | $1.40 | +0.06% | Buy |